ResMed Inc. (NYSE:RMD) CFO Brett Sandercock sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, June 15th. The shares were sold at an average price of $106.76, for a total value of $213,520.00. Following the completion of the sale, the chief financial officer now owns 67,072 shares in the company, valued at approximately $7,160,606.72. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Brett Sandercock also recently made the following trade(s):
- On Tuesday, May 15th, Brett Sandercock sold 2,000 shares of ResMed stock. The shares were sold at an average price of $101.52, for a total value of $203,040.00.
- On Monday, April 16th, Brett Sandercock sold 2,000 shares of ResMed stock. The shares were sold at an average price of $99.36, for a total value of $198,720.00.
Shares of ResMed opened at $106.10 on Wednesday, MarketBeat reports. ResMed Inc. has a 12-month low of $71.29 and a 12-month high of $107.67. The company has a market cap of $15.17 billion, a PE ratio of 37.62 and a beta of 0.93. The company has a current ratio of 3.48, a quick ratio of 2.85 and a debt-to-equity ratio of 0.39.
ResMed (NYSE:RMD) last announced its quarterly earnings data on Thursday, April 26th. The medical equipment provider reported $0.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.85 by $0.07. ResMed had a return on equity of 23.72% and a net margin of 13.52%. The company had revenue of $591.60 million for the quarter, compared to analysts’ expectations of $575.75 million. During the same quarter in the prior year, the business posted $0.71 EPS. The business’s revenue was up 15.1% compared to the same quarter last year. equities analysts expect that ResMed Inc. will post 3.5 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 14th. Stockholders of record on Thursday, May 10th were paid a dividend of $0.35 per share. This represents a $1.40 dividend on an annualized basis and a dividend yield of 1.32%. The ex-dividend date of this dividend was Wednesday, May 9th. ResMed’s dividend payout ratio is currently 49.65%.
Several institutional investors have recently made changes to their positions in RMD. Suntrust Banks Inc. raised its stake in ResMed by 27.1% in the 1st quarter. Suntrust Banks Inc. now owns 4,814 shares of the medical equipment provider’s stock valued at $473,000 after acquiring an additional 1,026 shares during the period. Amalgamated Bank raised its stake in ResMed by 6.3% in the 1st quarter. Amalgamated Bank now owns 32,059 shares of the medical equipment provider’s stock valued at $3,157,000 after acquiring an additional 1,909 shares during the period. CIBC World Markets Inc. bought a new stake in ResMed in the 1st quarter valued at $278,000. Xact Kapitalforvaltning AB raised its stake in ResMed by 40.5% in the 1st quarter. Xact Kapitalforvaltning AB now owns 22,829 shares of the medical equipment provider’s stock valued at $2,248,000 after acquiring an additional 6,575 shares during the period. Finally, Royal Bank of Canada raised its stake in ResMed by 51.5% in the 1st quarter. Royal Bank of Canada now owns 40,213 shares of the medical equipment provider’s stock valued at $3,959,000 after acquiring an additional 13,664 shares during the period. Institutional investors own 62.21% of the company’s stock.
Several equities research analysts have commented on RMD shares. Zacks Investment Research upgraded ResMed from a “hold” rating to a “buy” rating and set a $105.00 target price on the stock in a research note on Tuesday, February 20th. Needham & Company LLC restated a “hold” rating on shares of ResMed in a research note on Wednesday, March 7th. Citigroup cut ResMed from a “buy” rating to a “neutral” rating in a research note on Wednesday, April 4th. UBS Group cut ResMed from a “buy” rating to a “neutral” rating in a research note on Tuesday, April 24th. Finally, William Blair reiterated an “outperform” rating on shares of ResMed in a research note on Monday, April 16th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and four have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $76.67.
ResMed Company Profile
ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.
Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.